Opyl Ltd. (AU:OPL) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Opyl Limited has entered a strategic partnership with L39 Capital to launch a Biotech Fund, leveraging their proprietary TrialKey technology to drive investor returns. Opyl will gain an upfront payment, a significant equity stake in the AI Fund Manager, and a share of the fund’s fees, with ambitions to reach $100 million in assets under management within three years. This move not only creates a new revenue stream for Opyl but also underscores the potential of AI in revolutionizing biotech investment strategies.
For further insights into AU:OPL stock, check out TipRanks’ Stock Analysis page.